Tempus AI (Nasdaq: TEM) and Bristol Myers Squibb (NYSE: BMY) announced an expansion of their existing partnership, applying Tempus’s Lens AI-enabled analytical platform and multimodal real-world data library to five initial BMS clinical trial programs across solid tumor oncology and Alzheimer’s disease. The Tempus Bristol Myers Squibb collaboration builds on a prior arrangement centered on the Next Pathways program for advanced non-small cell lung cancer and now extends the analytical scope to lung, colon, and prostate cancers, as well as neuroscience.
The expanded agreement tasks Tempus with applying its Lens platform to optimize clinical trial design and improve the Probability of Technical and Regulatory Success across BMS’s development programs. Lens draws on Tempus’s library of de-identified multimodal records — combining clinical data with molecular and genomic profiles — to characterize patient populations, pressure-test trial assumptions, validate control-group parameters, and identify patient segments with the highest likelihood of responding to investigational therapies.
The collaboration covers five initial BMS clinical programs. In oncology, the work spans solid tumor indications including lung, colon, and prostate cancers. In neuroscience, the arrangement extends to Alzheimer’s disease drug development, making this one of the broader therapeutic applications of the Tempus platform disclosed to date. No specific BMS drug candidates, program names, trial identifiers, or ClinicalTrials.gov NCT numbers were disclosed in connection with the agreement.
Tempus describes Lens as an AI-enabled analytical environment built on what the company characterizes as one of the largest multimodal real-world data libraries in healthcare. The platform links de-identified clinical records to molecular subtypes, enabling analyses that the company says go beyond what traditional trial-design methods support. In the context of the BMS collaboration, Lens is being used not to generate drug candidates or run wet-lab experiments, but to inform development decisions — specifically, to assess whether trial assumptions are well-founded before studies are initiated or advanced.
The use of real-world data in pharma development to validate control-arm assumptions and refine patient-selection criteria is an established practice, but the integration of clinicogenomic data at the scale Tempus describes represents a more recent application of this approach. Ryan Fukushima, CEO of Data and Apps at Tempus, said the platform allows the companies to “connect the dots between clinical records and molecular subtypes” and to “uncover the hidden biological signals of unmet patient need.” Bryan Campbell, Senior Vice President of Drug Development Strategy and Innovation at BMS, said the collaboration allows the company to “rigorously pressure-test trial assumptions, better understand patient heterogeneity, and design studies with a higher probability of technical and regulatory success.”